Mouse Pax4 (UniProt P32115): research report
Claude Code
claude-haiku-5-5, claude-opus-5-5
14 citations
2026-11-08T08:09:59.509783
Mouse Pax4 (UniProt P32115): research report
1. Identity check
- Target: Paired box protein Pax-4, gene Pax4 (MGI:97488), Mus musculus, UniProt P32115. It belongs to the paired homeobox (PAX) family and carries an N-terminal paired domain (IPR001523), a paired-type homeodomain (IPR001356) and a C-terminal region. It has no octapeptide motif.
- Is the symbol ambiguous? No. Every primary paper used here studies mouse Pax4 in the pancreas or intestine. Its domains match a bipartite paired-domain plus homeodomain DNA-binding protein. PAX4 is closest to PAX6 within the family, and the two share a promoter binding site in islet genes.
- Isoforms: UniProt records three splice isoforms (P32115-1, the displayed sequence; -2; -3). No distinct function has been assigned to any of them.
2. Primary function: a DNA-binding transcriptional repressor
2.1 DNA binding
Smith et al. (1999) cloned a full-length Pax4 cDNA from a beta-cell library. They defined the protein's consensus binding site as a "bipartite consensus DNA binding sequence consisting of a homeodomain binding site separated from a paired domain binding site by 15 nucleotides." The paired half resembles the PAX6 paired-domain site. "The two proteins bind to common sequences in several islet genes, although with different relative affinities" [PMID:10567552, Mol Cell Biol 1999; DOI 10.1128/MCB.19.12.8272].
UniProt states that Pax4 binds "a common element in the glucagon, insulin and somatostatin promoters" and competes with PAX6 for it (PMID:10364449, Ritz-Laser et al. 1999; PMID:10567552). These sites in the glucagon (G1/G3), insulin and somatostatin promoters are among the best-characterised Pax4 target elements.
2.2 Repression
- Active repression, not only competition. Expressed in an alpha-cell line, Pax4 "represses transcription through the glucagon or insulin promoters or through an isolated PAX4 binding site." This "is not simply due to competition with the PAX6 transcriptional activator," because a GAL4–PAX4 fusion also represses through GAL4 sites. "Repressor activity maps to more than one domain within the molecule, although the homeodomain and carboxyl terminus give the strongest repression" PMID:10567552.
- Endogenous glucagon is silenced. Stable Pax4 expression in a rat glucagon-producing cell line "inhibits the endogenously expressed glucagon gene completely." Pax4 also "represses Pax6 independent transcription of the insulin promoter," which suggests active repression in addition to competition [PMID:10891400, Petersen et al., Mol Cell Biol Res Commun 2000].
2.3 Molecular function in summary
Pax4 is a sequence-specific, RNA polymerase II–dependent DNA-binding transcription repressor. It binds cis-regulatory sites through both its paired domain and its homeodomain. Its repression domains, chiefly the homeodomain and C-terminus, can act independently of DNA-binding competition. Its main physiological targets are genes that specify alpha-cell (and ghrelin/epsilon-cell) identity, above all Arx. Repression of the hormone genes themselves is shown mostly in cell lines.
3. Where it acts
- In the cell: the nucleus, on chromatin. UniProt lists nucleus and chromosome, inferred from the DNA-binding and transcription data in PMID:10567552. No dedicated localization study of the endogenous protein turned up. Nuclear action is a safe inference from its function.
- Tissue and timing:
- Expressed in the early pancreatic epithelium, "but is later restricted to beta cells" PMID:9121556.
- Pax4 mRNA "peaks at embryonic day 13.5 in the fetal mouse pancreas and is undetectable in adult islets" PMID:10567552.
- Expressed in Ngn3+ endocrine progenitors as an "early" factor, together with Nkx2.2, Nkx6.1 and Pdx1. The late factors Isl1, Brn4 and Pax6 mark mature endocrine cells (BMC Dev Biol 2009, 9:65).
- Also expressed in intestinal enteroendocrine progenitors PMID:22570716.
- A 0.25 kb 5′ fragment of the Pax4 gene is enough to drive expression in the endocrine pancreas (Göttingen dissertation).
4. Biological processes and pathway context
4.1 Beta- and delta-cell fate in the pancreatic islet (core role)
Sosa-Pineda et al. (1997) made the Pax4 knockout. It "results in the absence of mature insulin- and somatostatin-producing cells (beta and delta, respectively)... but glucagon-producing alpha cells are present in considerably higher numbers." The authors proposed that "early expression of Pax4 in a subset of endocrine progenitors is essential for the differentiation of the beta and delta cell lineages," with alpha cells as a default fate [PMID:9121556, Nature 1997]. Homozygous mutants develop severe diabetes and die within about three days of birth (UniProt, citing PMID:9121556).
Ghrelin-producing (epsilon) cells also expand in Pax4 mutants. As in Nkx2.2 mutants, "ghrelin cells replace insulin-producing β cells." This points to a shared insulin/ghrelin progenitor, with Nkx2.2 and Pax4 each required independently to specify beta-cell fate (PNAS 2004;101:2924–2929; PMC365721).
4.2 The Arx–Pax4 antagonism (central mechanism)
- Opposite knockout phenotypes. Arx loss gives "an early-onset loss of mature endocrine alpha cells with a concomitant increase in beta- and delta-cell numbers... exactly the opposite of the action of Pax4." Each mutant accumulates the other's transcripts, which suggests mutual repression [PMID:14561778, Collombat et al., Genes Dev 2003].
- Double mutants. In the combined absence of Arx and Pax4, mature alpha and beta cells are lost early and somatostatin (delta) cells form almost exclusively. Pax4 therefore also has an Arx-independent role in shaping the beta- versus delta-cell choice [PMID:15930104, Collombat et al., Development 2005].
- Ectopic expression. Pax4 driven by different promoters "forces endocrine precursor cells, as well as mature alpha cells, to adopt a beta cell destiny." The resulting glucagon deficiency triggers continuous regeneration of glucagon+ cells from duct-lining precursors, which then convert to beta cells. Pax4 misexpression also restores beta-cell mass after chemical ablation [PMID:19665969, Collombat et al., Cell 2009, PMC2792203].
- Shared function with Nkx2.2. One function Nkx2.2 and Pax4 share is to counteract Arx activity in early committed beta cells (BMC Dev Biol 2011, 11:52).
These studies place Pax4 within the Ngn3-initiated endocrine programme. Pax4 sits downstream of Ngn3, alongside Nkx2.2, and its main output is repression of Arx (the alpha-cell determinant) and of ghrelin/epsilon-cell identity. UniProt records Arx repression as "probably," and strong direct Arx-enhancer binding data for mouse Pax4 were not found.
4.3 Enteroendocrine cell subtype specification
In the mouse intestine, Arx and Pax4 also set enteroendocrine subtypes from Neurog3+ progenitors. Pax4 promotes enterochromaffin (serotonin) and D-cell (somatostatin) fates and restrains Arx-dependent subtypes: L (GLP-1), I (CCK), K (GIP), G and N cells [PMID:22570716, Beucher et al., PLoS One 2012, PMC3343025]. UniProt says this restraint works by repressing ARX, a claim marked "by similarity."
4.4 Adult beta-cell proliferation and survival (secondary, mostly gain-of-function)
- Rat and human islets. Adenoviral Pax4 caused a "3.5-fold increase in β-cell proliferation with a concomitant 1.9-, 4-, and 5-fold increase in Bcl-xL (antiapoptotic), c-myc, and Id2 mRNA." Pax4 transactivated the Bcl-xL and c-myc promoters, and a diabetes-linked mutant did so less efficiently. Adult rat islet Pax4 transcripts rose in response to activin A and betacellulin, through PI3K [Brun et al., J Cell Biol 2004;167:1123; rupress].
- Adult mouse beta cells. Conditional Pax4 expression protected against cytokine-induced apoptosis, by dampening selected NF-κB targets and raising Bcl-2. It also promoted beta-cell dedifferentiation and proliferation through MafA repression, with Cdk4 and c-myc going up (Lorenzo et al., Diabetes 2011; details taken from search snippets).
Caveat: these are overexpression results. Endogenous Pax4 is barely detectable in adult mouse islets PMID:10567552. They show what Pax4 can do, not established normal adult physiology. They are the likely source of the projected GO terms "negative regulation of apoptotic process" (GO:0043066) and "response to glucose/dexamethasone".
4.5 Limits of the regeneration role
GABA-induced alpha-to-beta-like cell conversion in mice happens through dampened Arx activity. Pax4 is reported as not required for it (Ben-Othman et al., Cell 2017; Silvano/Mansouri/Collombat commentary). Loss of Arx alone in adult alpha cells can also convert them to beta-like cells (Druelle et al.). So Pax4 is enough to reprogram cells but is not required for every route to beta-cell neogenesis. Reviews covering this: PMC4373662; typeset review.
5. Evolutionary and structural inference
- Pax4 is a vertebrate PAX paralog, most closely related to PAX6. The two bind overlapping paired-domain sites but have opposite outputs: PAX6 activates and PAX4 represses PMID:10567552.
- A paired domain plus a full paired-type homeodomain (S50 class) explains the bipartite site with a 15-nt spacer.
- PANTHER/IBA annotations (eye, brain, forebrain and sensory organ development; DNA-binding TF activity; nucleus) transfer family-level PAX functions. Of these, the DNA-binding and nucleus terms clearly apply to Pax4. The eye and brain development terms reflect PAX6 and other members, and no mouse Pax4 data support them.
6. Notes for annotation
| Aspect |
Well supported |
Weak or over-annotated |
| MF |
RNA Pol II cis-regulatory region sequence-specific DNA binding (GO:0000978); DNA-binding transcription repressor activity, RNA Pol II–specific (GO:0001227) [PMID:10567552, 10891400] |
Generic DNA binding (GO:0003677) and DNA-binding TF activity (GO:0003700) are true but less specific; double-stranded DNA binding (GO:0003690) is redundant |
| BP |
Type B pancreatic cell differentiation/development (GO:0003309) [PMID:9121556, 19665969]; negative regulation of transcription by RNA Pol II (GO:0000122) PMID:10567552; regulation of cell differentiation via enteroendocrine cell differentiation, e.g. enterochromaffin cell differentiation (GO:0035883) PMID:22570716; delta-cell differentiation [PMID:9121556, 15930104] |
Eye, brain, forebrain and sensory organ development (IBA, family transfer); circadian rhythm, response to glucose/dexamethasone, and anti-apoptosis (ISO/ISS from rat/human overexpression); insulin secretion-related terms |
| CC |
Nucleus; chromatin (inferred) |
Transcription regulator complex (GO:0005667) has no direct complex data |
7. Open questions and suggested experiments
- Map genome-wide Pax4 occupancy in E13.5–E15.5 endocrine progenitors (CUT&RUN/ChIP-seq on epitope-tagged endogenous Pax4) to test whether Arx and ghrelin are direct targets.
- Identify the corepressors behind the homeodomain and C-terminal repression domains, for example by Groucho/TLE or Sin3 proximity labelling, and test them with repression-domain mutants in vivo.
- Test whether endogenous Pax4 has any adult beta-cell role (inducible beta-cell-specific deletion under metabolic stress), given that the proliferation and survival data come from overexpression.
Sources
- Sosa-Pineda B et al. Nature 1997;386:399–402. PMID:9121556. doi:10.1038/386399a0
- Smith SB et al. Mol Cell Biol 1999;19:8272–80. PMID:10567552. PMC84911
- Ritz-Laser B et al. Diabetologia/BBRC 1999 (Pax4/Pax6 competition). PMID:10364449. Cited via UniProt; abstract not read.
- Petersen HV et al. Mol Cell Biol Res Commun 2000;3:249–54. PMID:10891400
- Collombat P et al. Genes Dev 2003;17:2591–603. PMID:14561778. PMC218152
- Collombat P et al. Development 2005;132:2969. PMID:15930104
- Collombat P et al. Cell 2009;138:449–62. PMID:19665969. PMC2792203
- Beucher A et al. PLoS One 2012;7:e36449. PMID:22570716. PMC3343025
- Ghrelin cells replace β cells, PNAS 2004: JCI ref, PMC365721
- Brun T et al. J Cell Biol 2004;167:1123: rupress
- Nkx2.2 and Pax4 vs Arx, BMC Dev Biol 2011;11:52: link
- Nkx2.2 targets / early endocrine factors, BMC Dev Biol 2009;9:65: PDF
- Pax4 promoter dissertation: Göttingen
- GABA/Arx regeneration: Ben-Othman, MPG commentary, Druelle
- Reviews: PMC4373662, typeset, PMC3561089
- UniProtKB P32115 (local
genes/mouse/Pax4/Pax4-uniprot.txt)
How the sources were checked:
- The abstracts of PMIDs 9121556, 10567552, 10891400, 14561778, 19665969 and 22570716 were read from the local publications/ cache.
- PMIDs 10364449 and 15930104 are cited through UniProt and partial abstracts.
- The Lorenzo 2011 and PNAS 2004 details come from web search snippets, not full texts.
- No source from 2023–2026 specific to mouse Pax4 mechanism was found, so the core picture rests on the 1997–2012 primary literature.
Citations
- https://bmcdevbiol.biomedcentral.com/track/pdf/10.1186/1471-213X-9-65
- https://ediss.uni-goettingen.de/handle/11858/00-1735-0000-0006-ABEE-6;jsessionid=AAEABBFBEB387A45BCB6AA55D28F895B
- https://jci.org/references/scholar/35112/B11
- https://pmc.ncbi.nlm.nih.gov/articles/PMC365721/
- https://www.biomedcentral.com/1471-213X/11/52
- https://rupress.org/jcb/article/167/6/1123/51557/The-diabetes-linked-transcription-factor-PAX4
- https://scite.ai/authors/nouha-ben-othman-4YZ8k3
- https://pure.mpg.de/pubman/item/item_2468345_3/component/file_2468346/2468345.pdf
- https://scite.ai/authors/noemie-druelle-lXZ2r3
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4373662
- https://typeset.io/pdf/role-of-transcription-factors-in-the-transdifferentiation-of-3io36ih86i.pdf
- https://pmc.ncbi.nlm.nih.gov/articles/PMC218152
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2792203
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3561089